Bardoxolone Methyl Improves Kidney Function in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes: Post-Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes Study

GFR Decline as an Alternative End Point to Kidney Failure in Clinical Trials: A Meta-analysis of Treatment Effects From 37 Randomized Trials

(2014) Lesley A. Inker et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

GFR Decline as an End Point for Clinical Trials in CKD: A Scientific Workshop Sponsored by the National Kidney Foundation and the US Food and Drug Administration

(2014) Andrew S. Levey et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Mechanisms Contributing to Adverse Cardiovascular Events in Patients with Type 2 Diabetes Mellitus and Stage 4 Chronic Kidney Disease Treated with Bardoxolone Methyl

(2014) Melanie P. Chin et al.   AMERICAN JOURNAL OF NEPHROLOGY

Risk Factors for Heart Failure in Patients With Type 2 Diabetes Mellitus and Stage 4 Chronic Kidney Disease Treated With Bardoxolone Methyl

(2014) Melanie P. Chin et al.   JOURNAL OF CARDIAC FAILURE

Rationale and Trial Design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: The Occurrence of Renal Events (BEACON)

(2013) Dick de Zeeuw et al.   AMERICAN JOURNAL OF NEPHROLOGY

Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease

(2013) Stacey Ruiz et al.   KIDNEY INTERNATIONAL

Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trial

(2013) H. J. Lambers Heerspink et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease

(2013) Dick de Zeeuw et al.   NEW ENGLAND JOURNAL OF MEDICINE

The synthetic triterpenoid RTA dh404 (CDDO-dhTFEA) restores Nrf2 activity and attenuates oxidative stress, inflammation, and fibrosis in rats with chronic kidney disease

(2013) Mohammad A. Aminzadeh et al.   XENOBIOTICA

The synthetic triterpenoid RTA dh404 (CDDO-dhTFEA) restores endothelial function impaired by reduced Nrf2 activity in chronic kidney disease

(2013) Mohammad A. Aminzadeh et al.   Redox Biology

The synthetic triterpenoid, RTA 405, increases the glomerular filtration rate and reduces angiotensin II–induced contraction of glomerular mesangial cells

(2012) Yanfeng Ding et al.   KIDNEY INTERNATIONAL

Effect of Bardoxolone Methyl on Kidney Function in Patients with T2D and Stage 3b–4 CKD

(2011) Pablo E. Pergola et al.   AMERICAN JOURNAL OF NEPHROLOGY

New Synthetic Triterpenoids: Potent Agents for Prevention and Treatment of Tissue Injury Caused by Inflammatory and Oxidative Stress

(2011) Michael B. Sporn et al.   JOURNAL OF NATURAL PRODUCTS

Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes

(2011) Pablo E. Pergola et al.   NEW ENGLAND JOURNAL OF MEDICINE

Transcriptional Regulation of Renal Cytoprotective Genes by Nrf2 and Its Potential Use as a Therapeutic Target to Mitigate Cisplatin-Induced Nephrotoxicity

(2010) L. M. Aleksunes et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Avosentan for Overt Diabetic Nephropathy

(2010) J. F.E. Mann et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY